TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid

Nanna Møller Sørensen; Per Byström; Ib J. Christensen; Åke Berglund; Hans Jørgen Nielsen; Nils Brünner; Bengt Glimelius

doi:10.1158/1078-0432.CCR-07-0186

TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid

Nanna Møller Sørensen, Per Byström, Ib J. Christensen, Åke Berglund, Hans Jørgen Nielsen, Nils Brünner, Bengt Glimelius

66 Citations (Scopus)

743 Downloads (Pure)

Abstract

Udgivelsesdato: JUL 15

Original language	English
Journal	Clinical Cancer Research
Volume	13
Issue number	14
Pages (from-to)	4117-4122
Number of pages	6
ISSN	1078-0432
DOIs	https://doi.org/10.1158/1078-0432.CCR-07-0186
Publication status	Published - 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-07-0186

FulltextFinal published version, 145 KB

Cite this

Sørensen, N. M., Byström, P., Christensen, I. J., Berglund, Å., Nielsen, H. J., Brünner, N., & Glimelius, B. (2007). TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clinical Cancer Research, 13(14), 4117-4122. https://doi.org/10.1158/1078-0432.CCR-07-0186

TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. / Sørensen, Nanna Møller; Byström, Per; Christensen, Ib J. et al.

In: Clinical Cancer Research, Vol. 13, No. 14, 2007, p. 4117-4122.

Research output: Contribution to journal › Journal article › Research › peer-review

Sørensen, NM, Byström, P, Christensen, IJ, Berglund, Å, Nielsen, HJ, Brünner, N & Glimelius, B 2007, 'TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid', Clinical Cancer Research, vol. 13, no. 14, pp. 4117-4122. https://doi.org/10.1158/1078-0432.CCR-07-0186

@article{844bf240a1c211ddb6ae000ea68e967b,

title = "TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid",

abstract = "Udgivelsesdato: JUL 15",

author = "S{\o}rensen, {Nanna M{\o}ller} and Per Bystr{\"o}m and Christensen, {Ib J.} and {\AA}ke Berglund and Nielsen, {Hans J{\o}rgen} and Nils Br{\"u}nner and Bengt Glimelius",

year = "2007",

doi = "10.1158/1078-0432.CCR-07-0186",

language = "English",

volume = "13",

pages = "4117--4122",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research (A A C R)",

number = "14",

}

TY - JOUR

T1 - TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid

AU - Sørensen, Nanna Møller

AU - Byström, Per

AU - Christensen, Ib J.

AU - Berglund, Åke

AU - Nielsen, Hans Jørgen

AU - Brünner, Nils

AU - Glimelius, Bengt

PY - 2007

Y1 - 2007

N2 - Udgivelsesdato: JUL 15

AB - Udgivelsesdato: JUL 15

U2 - 10.1158/1078-0432.CCR-07-0186

DO - 10.1158/1078-0432.CCR-07-0186

M3 - Journal article

C2 - 17634538

SN - 1078-0432

VL - 13

SP - 4117

EP - 4122

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 14

ER -